
    
      In 2018,the results of IMpower 133 were reported on WCLC.Meanwhile,the data was published in
      NEJM.Atezolizumab combined with carboplatin and etoposide for extensive stage small cell lung
      cancer was recommended as the first by NCCN guidelines quickly.

      Atezolizumab plus chemotherapy was approved by NMPA on Feb 13,2020,making Atezolizumab for 1L
      ES-SCLC in China.

      Real world study can reflect the efficacy and safety of treatment in clinical practice.Based
      on the research of public database,the prospective cohort study had been reported,but the
      study based on Chinese patients still left weak point.
    
  